Wassam EL Din Hadad EL Shafey
Ticagrelor, a novel direct, reversibly binding P2Y12 antagonist, has better pharmacodynamic effects and improves clinical outcomes compared with clopidogrel in the setting of ACS. However, ticagrelor-related dyspnea and bradyarrhythmias have been observed in the PLATO trial, here in my case I will present a case of ticagrelor side effects and how it may burden the course of hospital stay.
